4 result(s) displayed (1 - 4 of 4):

Watson-Arrow latest in emerging markets trend (from Corporate Dealmaker)

As it tries to keep up with its main rivals, Watson Pharmaceuticals Inc.'s (NYSE: WPI) $1.75 billion acquisition of privately held Arrow Group highlights a growing trend in Big Pharma expanding into emerging markets via dealmaking.The deal gives Watson a significant presence outside of the U.S. as Arrow, which is...

Posted on June 17, 2009 12:37 PM

Teva Pharma, bettered by Barr, eyes more M&A (from Corporate Dealmaker)

World No. 1 generic drug maker Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) beat its profit forecast as its $7.46 billion acquisition of Montvale, N.J., rival Barr Pharmaceuticals Inc. is paying off more than expected and it recorded record-breaking sales of Copaxone, a drug used in multiple sclerosis treatment.The Israeli drug company,...

Posted on May 5, 2009 3:12 PM

Whew! Teva gets credit deal for $7.5B Barr purchase (from Corporate Dealmaker)

Companies around the globe are struggling with credit, for example, there's the financing trouble with Hexion Specialty Chemicals Inc.'s $10.5 billion purchase of Huntsman Corp. But Israeli generic drugmaker Teva Pharmaceutical Industries Ltd. lucked out with its $7.46 billion acquisition of Montvale, N.J.'s Barr Pharmaceuticals Inc. A syndicate of...

Posted on October 28, 2008 2:14 PM

Nothing generic about returns on Hospira's Mayne Pharma deal (from Corporate Dealmaker)

Hospira Inc. CEO Christopher Begley said in a statement in September 2006 that the $2.1 billion purchase of Australian generic cancer drugs group Mayne Pharma Ltd. would add to Hospira's earnings per share in 2007. Lo and behold, the company just reported a 60% jump in fourth-quarter net income. No...

Posted on February 29, 2008 12:17 PM